Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 402

Results For "LA"

8534 News Found

Amgen opens new technology and innovation site in Hyderabad
Digitisation | February 25, 2025

Amgen opens new technology and innovation site in Hyderabad

Amgen India investment totals $200 million through 2025


Teva and Sanofi present new outcome from Phase 2b study of duvakitug
News | February 25, 2025

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025


Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
News | February 22, 2025

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market


Roche Diagnostics India screens 5,000 children for eye health
Healthcare | February 21, 2025

Roche Diagnostics India screens 5,000 children for eye health

Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children


USFDA issues Form-483 for Piramal Pharma's facility at Turbhe
Drug Approval | February 21, 2025

USFDA issues Form-483 for Piramal Pharma's facility at Turbhe

Observations are largely around improvement of procedures and practices


Wanbury reports 88% drop in Q3 FY25 PAT
News | February 21, 2025

Wanbury reports 88% drop in Q3 FY25 PAT

Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25


KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
Healthcare | February 21, 2025

KIMS enters into agreement to manage Splendid Hospitals, Hyderabad

Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals


Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
Drug Approval | February 21, 2025

Korea’s MFDS completes inspection at Concord Biotech's Dholka unit

The inspection was successfully completed


Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer
Drug Approval | February 20, 2025

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved